{"id":"W4413114117","doi":"10.1002/cpdd.1583","title":"Safety, Tolerability, and Pharmacokinetics of the Long‐Acting SARS‐CoV‐2–Neutralizing Monoclonal Antibody Combination AZD7442 (Tixagevimab/Cilgavimab) in Healthy Chinese Adults","year":2025,"lang":"en","type":"article","venue":"Clinical Pharmacology in Drug Development","topic":"SARS-CoV-2 and COVID-19 Research","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"ca_institutions":"Institute of Infection and Immunity","funders":"AstraZeneca","keywords":"Medicine; Tolerability; Coronavirus disease 2019 (COVID-19); Pharmacokinetics; Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2); Virology; Monoclonal antibody; 2019-20 coronavirus outbreak; Pharmacology; Antibody; Immunology; Adverse effect; Internal medicine; Infectious disease (medical specialty); Outbreak; Disease","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.003307702,0.0002912697,0.0008503192,0.0003703382,0.0001296228,0.00001485217,0.000395266,0.0002168262,0.00001627094],"category_scores_gemma":[0.0007711737,0.0002289059,0.0001324635,0.001006244,0.0004444358,0.00009280511,0.0006240891,0.001366497,0.000006746322],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0004396097,"about_ca_system_score_gemma":0.001210467,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0001896702,"about_ca_topic_score_gemma":0.0003329255,"domain_scores_codex":[0.9956741,0.0007271751,0.001975668,0.00066737,0.0003999408,0.0005557624],"domain_scores_gemma":[0.9973045,0.001861388,0.0002834489,0.0002551048,0.0002293218,0.00006624656],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"observational","study_design_gemma":"observational","study_design_scores_codex":[0.003992257,0.002194966,0.95084,0.0007690903,0.0001019507,0.00006772682,0.001099692,0.00000783697,0.01575577,0.00002521123,0.0004131906,0.02473232],"study_design_scores_gemma":[0.01496235,0.000184362,0.9204794,0.0005218214,0.00005585085,0.00001125295,0.0001378014,0.001864083,0.05623908,0.000251014,0.005080281,0.000212697],"study_design_candidate":"observational","study_design_consensus":"observational","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9876119,0.0006319882,0.00003688678,0.007927519,0.001378215,0.001508876,0.000004139378,0.00003112344,0.0008693778],"genre_scores_gemma":[0.9649537,0.0002024414,0.0003316411,0.03429744,0.0000893576,0.00007412441,0.000009566293,0.00001892112,0.00002283745],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.04048331,"threshold_uncertainty_score":0.933451,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.05256922252441759,"score_gpt":0.4732816387254207,"score_spread":0.4207124162010031,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}